These findings establish a proof of concept for ACE-tRNA-mediated therapy as a broadly applicable approach for treating nonsense variant-associated Alport syndrome, including cases where conventional readthrough inducers are ineffective. The gene discussed is ACE; the disease is Alport syndrome.